Biotechnology
Helix BioPharma Reports Reduced Loss, Strengthens Cash Position Amid Strategic Financing
Helix BioPharma Corp. reported a narrowed net loss for the three- and nine-month periods ended April 30, 2026, and a significant cash increase to $2.84 million, driven by a private placement that supports near-term operations and preparations for a U.S. exchange listing.
VERAXA Biotech Begins Trading on Nasdaq After Business Combination
VERAXA Biotech (VRXA) started trading on Nasdaq following a business combination with Voyager Acquisition Corp., advancing its oncology pipeline with proprietary BiTAC platform targeting solid tumors.
Cardio Diagnostics Leverages AI, Genetics and Epigenetics to Transform Cardiovascular Risk Detection
Cardio Diagnostics Holdings uses AI and epigenetic biomarkers to enhance cardiovascular disease prevention and management, offering a suite of personalized solutions.
Helix BioPharma Reports Reduced Losses, Secures $3.67M Financing to Extend Runway
Helix BioPharma Corp. announced narrower net losses for the nine months ended April 30, 2026, and raised $3.67 million through convertible debentures, strengthening its cash position to approximately twelve months of operating runway while advancing preparations for a U.S. exchange listing.
FIU Researchers Discover Method to Extend Immune Cell Lifespan, Potentially Boosting CAR-T Therapy Effectiveness
A new study from FIU researchers has found a way to extend the lifespan and efficacy of immune cells used in CAR-T therapy, which could improve treatment outcomes for blood cancers and potentially solid tumors.
VERAXA Biotech Begins Trading on NASDAQ, Advances Diversified Oncology Pipeline
VERAXA Biotech AG has started trading on NASDAQ under ticker VRXA, advancing a pipeline of antibody-based cancer therapies including BiTAC platform technology aimed at improving tumor targeting and reducing toxicity.
VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination
VERAXA Biotech AG, formed through a merger with Voyager Acquisition Corp., starts trading on Nasdaq under ticker VRXA, advancing its BiTAC platform for cancer therapies with new financing.
Onco-Innovations Advances PNKP Inhibitor ONC010 as Emerging DDR Therapy
Onco-Innovations Ltd. is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways, positioning itself in the DDR therapy market with AI-driven precision oncology capabilities.
Quantum BioPharma Completes Phase 1 Trial for Multiple Sclerosis Therapy Lucid-MS
Quantum BioPharma announces completion of Phase 1 clinical studies for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and submission of an IND application to the FDA.
Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS Program, Completes Phase 1 Trials
Quantum BioPharma has completed Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND with the FDA, addressing the critical unmet need for neuroprotective treatments.
TransCode Therapeutics to Host R&D Webcast as It Advances Phase 2a Trial for Colorectal Cancer
TransCode Therapeutics will provide strategic and clinical updates during its first live R&D webcast, anchored by its Phase 2a trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, highlighting progress in RNA-based oncology treatments.
GeoVax Study Shows Gedeptin May Enhance Checkpoint Inhibitor Responses in Resistant Tumors
Peer-reviewed research in JCI Insight demonstrates GeoVax's Gedeptin platform can sensitize resistant tumors to immune checkpoint inhibitors and activate systemic anti-tumor immunity, potentially broadening cancer immunotherapy efficacy.
Lifordi Immunotherapeutics Reports Positive Phase 1 Data for LFD-200 in Autoimmune Disease
Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, shows anti-inflammatory activity without systemic steroid toxicity, with patient dosing ongoing in rheumatoid arthritis.
Quantum BioPharma Diversifies Pipeline to Address Neurological and Wellness Markets
Quantum BioPharma is advancing a novel MS therapy and expanding into alcohol health with unbuzzd, targeting unmet needs in neurological care and consumer wellness.
Regentis Biomaterials' GelrinC Targets Large Untapped Market for Off-the-Shelf Cartilage Repair
Regentis Biomaterials is advancing its GelrinC platform toward commercialization, aiming to fill the gap in FDA-approved off-the-shelf regenerative cartilage repair for the 470,000 annual U.S. knee cartilage damage cases.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial as Drug-Delivery Market Nears $410 Billion Opportunity
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial examining the growing drug-delivery market, highlighting its Sapu003 and Deciparticle platform as nanotechnology-driven approaches to improve existing therapies.
Kairos Pharma Expands Oncology Pipeline with Proposed Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma's mid-year update reveals plans to acquire CL-741, a Phase 1-ready oral c-MET inhibitor, expand clinical trials for ENV-105, and secure over $8 million in non-dilutive funding, signaling significant pipeline growth and potential advancements in cancer treatment.
Helix BioPharma Raises C$3.67M in Convertible Debenture Offering to Fund Drug Development
Helix BioPharma Corp. closed a private placement of convertible debentures raising C$3.67 million, with proceeds earmarked for working capital and advancement of its oncology drug pipeline.
Quantum BioPharma Builds Diversified Pipeline Targeting Neurological and Wellness Markets
Quantum BioPharma Ltd. advances LUCID-MS for multiple sclerosis and expands into alcohol metabolism with unbuzzd, addressing unmet needs in neurology and wellness.
LIXTE Biotechnology Prices $16.6 Million Registered Direct Offering to Strengthen Balance Sheet
LIXTE Biotechnology Holdings has priced a $16.6 million registered direct offering with accredited investors, which the company says will materially strengthen its balance sheet and provide flexibility for strategic priorities.
Oncotelic Therapeutics Expands Sapu003 Phase 1b Program with Global CRO Appointment, Signaling Shift to Multinational Development
Oncotelic Therapeutics and Sapu Nano expand the Phase 1b trial for Sapu003, appointing Global Clinical Trials to lead international execution, marking a transition from an Australia-based study to a multinational strategy.
TransCode Therapeutics Reports Positive Phase 1a Results for TTX-MC138, Paving Way for Phase 2a Trial
TransCode Therapeutics announced positive Phase 1a results for its investigational microRNA-10b inhibitor TTX-MC138, showing durable disease stabilization and no dose-limiting toxicities, supporting advancement to Phase 2a clinical development.
Platform Biotech Models Attract Investor Attention as Drug-Delivery Market Nears $410 Billion
Biotechnology companies are increasingly focusing on platform technologies for drug delivery to maximize existing therapies, with the market projected to reach $410 billion, drawing investor interest to firms like Oncotelic Therapeutics.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Oncotelic Therapeutics is featured in a BioMedWire editorial that examines how biotech companies use advanced drug-delivery technologies and AI platforms to enhance therapies, highlighting Oncotelic's Sapu003, Deciparticle, and PDAOAI initiatives.
VolitionRx Expands Patent Portfolio with Ebola Triage Application
VolitionRx has filed a patent for using its Nu.Q technology to triage and monitor potential Ebola patients, aiming to provide low-cost bedside testing in resource-limited outbreak zones.
Lexaria Bioscience to Attend BIO International Convention Amid Record Business Development Interest
Lexaria Bioscience Corp. announces its attendance at the BIO International Convention in San Diego, highlighting a surge in partnership interest for its DehydraTECH drug delivery platform, which could lead to significant collaborations with pharmaceutical giants and biotech firms.
GeoVax CEO Sees Renewed Strategic Interest in Vaccine Platforms as Industry Shifts Toward Health Security
GeoVax Labs CEO David Dodd comments on recent pharmaceutical acquisitions, highlighting a strategic shift toward vaccine innovation and health security amid rising global infectious disease threats.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with Novel Off-the-Shelf Solution
Regentis Biomaterials' GelrinC platform offers a potential first-in-class, ready-to-use knee cartilage repair treatment with superior pain relief and faster recovery, advancing through U.S. Phase III trials.
Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
iOrganBio Adds Leading Neurobiologist Dr. Zhiping Pang to Scientific Advisory Board
iOrganBio appoints Dr. Zhiping Pang, a top expert in human neuron biology and neuropsychiatric disorders, to its Scientific Advisory Board, strengthening its position in AI-enabled human cell manufacturing for research and therapeutics.